Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Puri Website

Anu Puri, Ph.D.

Selected Publications

1)  Puri A.
Phototriggerable Liposomes: Current Research and Future Perspectives (Invited Review).
Pharmaceutics. 6: 1-15, 2014.
Full Text Article. [Journal]
2)  Smith B, Lyakhov I, Loomis K, Needle D, Baxa U, Yavlovich A, Capala J, Blumenthal R, Puri A.
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
J Control Release. 153: 187-94, 2011.
3)  Rawat SS, Gallo SA, Eaton J, Martin TD, Ablan S, KewalRamani VN, Wang JM, Blumenthal R, Puri A.
Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion.
J Virol. 78: 7360-8, 2004.
4)  Puri A, Booy FP, Doms RW, White JM, Blumenthal R.
Conformational changes and fusion activity of influenza virus hemagglutinin of the H2 and H3 subtypes: effects of acid pretreatment.
J Virol. 64: 3824-32, 1990.
5)  Puri A, Winick J, Lowy RJ, Covell D, Eidelman O, Walter A, Blumenthal R.
Activation of vesicular stomatitis virus fusion with cells by pretreatment at low pH.
J Biol Chem. 263: 4749-53, 1988.
6)  Yavlovich A, Viard M, Gupta K, Sine J, Vu M, Blumenthal R, Tata DB, Puri A.
Low-visibility light-intensity laser-triggered release of entrapped calcein from 1,2-bis (tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine liposomes is mediated through a type I photoactivation pathway.
Int J Nanomedicine. 8: 2575-87, 2013.
7)  Gupta K, Jang H, Harlen K, Puri A, Nussinov R, Schneider JP, Blumenthal R.
Mechanism of Membrane Permeation Induced by Synthetic ß-Hairpin Peptides.
Biophys. J. 105: 2093-103, 2013.
8)  Yavlovich A, Singh A, Blumenthal R, Puri A.
A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubcin to cells.
Biochim. Biophys. Acta. 1808: 117-26, 2011.
9)  Puri A, Jang H, Yavlovich A, Masood AM, Veenstra TD, Luna C, Aranda-Espinoza H, Nussinov R, Blumenthal R.
Material Properties of Matrix Lipids Determine Conformation and Intermolecular Reactivity of a Diacetylenic Phosphatidylcholine in the Lipid Bilayer.
Langmuir : the ACS journal of surfaces and colloids. 2011.
10)  Puri A, Blumenthal R.
Polymeric Lipid Assemblies as Novel Theranostic Tools.
Accounts of chemical research. 2011.
11)  Colantonio S, Simpson JT, Fisher RJ, Yavlovich A, Belanger JM, Puri A, Blumenthal R.
Quantitative Analysis of Phospholipids Using Nanostructured Laser Desorption Ionization Targets.
Lipids. 2011.
12)  Yavlovich A, Smith B, Gupta K, Blumenthal R, Puri A.
Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications.
Molecular membrane biology. 2010.
13)  Rosa Borges A, Wieczorek L, Johnson B, Benesi AJ, Brown BK, Kensinger RD, Krebs FC, Wigdahl B, Blumenthal R, Puri A, McCutchan FE, Birx DL, Polonis VR, Schengrund CL.
Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.
Virology. 2010.
14)  Puri A.
Nanoparticles: Crossing barriers and membrane interactions.
Molecular membrane biology. 2010.
15)  Loomis K, Smith B, Feng Y, Garg H, Yavlovich A, Campbell-Massa R, Dimitrov DS, Blumenthal R, Xiao X, Puri A.
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.
Experimental and molecular pathology. 2010.
16)  Yavlovich A, Singh A, Tarasov S, Capala J, Blumenthal R, Puri A.
Journal of thermal analysis and calorimetry. 98: 97-104, 2009.
17)  Puri A, Blumenthal R.
HIV type 1 Entry Correlates with Plasma Membrane Microdomain Lateral Assemblies of Receptors: Implications in HIV/AIDS treatment.
Journal of Viral Entry. 3(3): 101-13, 2009.
18)  Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R.
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.
Crit Rev Ther Drug Carrier Syst. 26: 523-80, 2009.
19)  Ramakrishnan B, Boeggeman E, Manzoni M, Zhu Z, Loomis K, Puri A, Dimitrov DS, Qasba PK.
Multiple site-specific in vitro labeling of single-chain antibody.
Bioconjug. Chem. 20: 1383-9, 2009.
20)  Boeggeman E, Ramakrishnan B, Pasek M, Manzoni M, Puri A, Loomis KH, Waybright TJ, Qasba PK.
Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection.
Bioconjug. Chem. 2009.
21)  Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK.
Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells.
Int. J. Oncol. 32: 1119-23, 2008.
22)  Garg H, Francella N, Tony KA, Augustine LA, Barchi JJ, Fantini J, Puri A, Mootoo DR, Blumenthal R.
Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
Antiviral Res. 80: 54-61, 2008.
23)  Puri A, Kramer-Marek G, Campbell-Massa R, Yavlovich A, Tele SC, Lee SB, Clogston JD, Patri AK, Blumenthal R, Capala J.
HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents.
Journal of liposome research. 1-15, 2008.
24)  Jacobs A, Garg H, Viard M, Raviv Y, Puri A, Blumenthal R.
HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: Implications for therapy and vaccine development.
Vaccine. 2008.
25)  Rawat SS, Zimmerman C, Johnson BT, Cho E, Lockett SJ, Blumenthal R, Puri A.
Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion.
Mol. Membr. Biol. 25: 83-94, 2008.
26)  Sharma A, Raviv Y, Puri A, Viard M, Blumenthal R, Maheshwari RK.
Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide.
Biochem Biophys Res Commun. 368(2): 453, 2007.
27)  Singh A, Lawson G, Shivakrupa R, Johnson B, Blumenthal R, Puri A.
Piroxicam Entrapped In Head-Group Polymerized Liposomes Inhibits Proliferation of IC2 Mast Cells In Vitro (Materials Research Symposium on Engineered Nanoscale Materials for the Diagnosis and Treatment of Diseases).
Volume 1019E. p. 1019-FF02-07. [Meeting Proceeding]
28)  Lund N, Branch DR, Mylvaganam M, Chark D, Ma XZ, Sakac D, Binnington B, Fantini J, Puri A, Blumenthal R, Lingwood CA.
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection.
AIDS. 20: 333-343, 2006.
29)  Rawat SS, Viard M, Gallo SA, Blumenthal R, Puri A.
Sphingolipids, cholesterol, and HIV-1: A paradigm in viral fusion.
Glycoconj J. 23: 189-97, 2006.
30)  Wexler-Cohen Y, Johnson BT, Puri A, Blumenthal R, Shai Y.
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide, Dp178.
J Biol Chem. 281(14): 9005-10, 2006.
31)  Ablan S, Rawat SS, Viard M, Wang JM, Puri A, Blumenthal R.
The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.
Virol J. 3: 104, 2006.
32)  Ray PE, Soler-García AA, Xu L, Soderland C, Blumenthal R, Puri A.
Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism.
Pediatr Nephrol. 20(10): 1401-9, 2005.
33)  Rawat SS, Johnson BT, Puri A.
Sphingolipids: Modulators of HIV-1 Infection and Pathogenesis.
Biosci Rep. 25: 329-43, 2005.
34)  Puri A, Rawat SS, Lin HM, Finnegan CM, Mikovits J, Ruscetti FW, Blumenthal R.
An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells.
AIDS. 18: 849-58, 2004.
35)  Finnegan CM, Rawat SS, Puri A, Wang JM, Ruscetti FW, Blumenthal R.
Ceramide, a target for antiretroviral therapy.
Proc Natl Acad Sci U S A. 101: 15452-7, 2004.
36)  Rawat SS, Eaton J, Gallo SA, Martin TD, Ablan S, Ratnayake S, Viard M, KewalRamani VN, Wang JM, Blumenthal R, Puri A.
Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion.
Virology. 318: 55-65, 2004.
37)  Viard M, Parolini I, Rawat SS, Fecchi K, Sargiacomo M, Puri A, Blumenthal R.
The role of glycosphingolipids in HIV signaling, entry and pathogenesis.
Glycoconj J. 20: 213-22, 2004.
38)  Rawat SS, Viard M, Gallo SA, Rein A, Blumenthal R, Puri A.
Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review).
Mol Membr Biol. 20: 243-54, 2003.
39)  Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R.
The HIV Env-mediated fusion reaction.
Biochim Biophys Acta. 1614: 36-50, 2003.
40)  Remeta DP, Krumbiegel M, Minetti CA, Puri A, Ginsburg A, Blumenthal R.
Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin.
Biochemistry. 41: 2044-54, 2002.
41)  Blumenthal R, Gallo SA, Viard M, Raviv Y, Puri A.
Fluorescent lipid probes in the study of viral membrane fusion.
Chem Phys Lipids. 116: 39-55, 2002.
42)  Puri A, Paternostre M, Blumenthal R.
Lipids in viral fusion.
Methods Mol Biol. 199: 61-81, 2002.
43)  Ablan S, Rawat SS, Blumenthal R, Puri A.
Entry of influenza virus into a glycosphingolipid-deficient mouse skin fibroblast cell line.
Arch Virol. 146: 2227-38, 2001.
44)  Gallo SA, Puri A, Blumenthal R.
HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process.
Biochemistry. 40: 12231-6, 2001.
45)  Hug P, Lin HM, Korte T, Xiao X, Dimitrov DS, Wang JM, Puri A, Blumenthal R.
Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5.
J Virol. 74: 6377-85, 2000.
46)  Puri A, Riley JL, Kim D, Ritchey DW, Hug P, Jernigan K, Rose P, Blumenthal R, Carroll RG.
Influenza virus upregulates CXCR4 expression in CD4+ cells.
AIDS Res Hum Retroviruses. 16: 19-25, 2000.
47)  Raviv Y, Puri A, Blumenthal R.
P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane.
FASEB J. 14: 511-5, 2000.
48)  Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, Lubkowski J.
The structure of human beta-defensin-2 shows evidence of higher order oligomerization.
J Biol Chem. 275: 32911-8, 2000.
49)  Jernigan KM, Blumenthal R, Puri A.
Varying effects of temperature, Ca(2+) and cytochalasin on fusion activity mediated by human immunodeficiency virus type 1 and type 2 glycoproteins.
FEBS Lett. 474: 246-51, 2000.
50)  Puri A, Hug P, Jernigan K, Rose P, Blumenthal R.
Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion.
Biosci Rep. 19: 317-25, 1999.
51)  Puri A, Hug P, Muñoz-Barroso I, Blumenthal R.
Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells.
Biochem Biophys Res Commun. 242: 219-25, 1998.
52)  Puri A, Hug P, Jernigan K, Barchi J, Kim HY, Hamilton J, Wiels J, Murray GJ, Brady RO, Blumenthal R.
The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein.
Proc Natl Acad Sci U S A. 95: 14435-40, 1998.
53)  Pak CC, Puri A, Blumenthal R.
Conformational changes and fusion activity of vesicular stomatitis virus glycoprotein: [125I]iodonaphthyl azide photolabeling studies in biological membranes.
Biochemistry. 36: 8890-6, 1997.
54)  Puri A, Morris SJ, Jones P, Ryan M, Blumenthal R.
Heat-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing HIV-1 envelope glycoproteins.
Virology. 219: 262-7, 1996.
55)  Puri A, Krumbiegel M, Dimitrov D, Blumenthal R.
A new approach to measure fusion activity of cloned viral envelope proteins: fluorescence dequenching of octadecylrhodamine-labeled plasma membrane vesicles fusing with cells expressing vesicular stomatitis virus glycoprotein.
Virology. 195: 855-8, 1993.
56)  Bagai S, Puri A, Blumenthal R, Sarkar DP.
Hemagglutinin-neuraminidase enhances F protein-mediated membrane fusion of reconstituted Sendai virus envelopes with cells.
J Virol. 67: 3312-8, 1993.
57)  Puri A, Clague MJ, Schoch C, Blumenthal R.
Kinetics of fusion of enveloped viruses with cells.
Methods Enzymol. 220: 277-87, 1993.
58)  Krumbiegel M, Dimitrov DS, Puri A, Blumenthal R.
Dextran sulfate inhibits fusion of influenza virus and cells expressing influenza hemagglutinin with red blood cells.
Biochim Biophys Acta. 1110: 158-64, 1992.
59)  Puri A, Dimitrov DS, Golding H, Blumenthal R.
Interactions of CD4+ plasma membrane vesicles with HIV-1 and HIV-1 envelope glycoprotein-expressing cells.
J Acquir Immune Defic Syndr. 5: 915-20, 1992.
60)  Puri A, Grimaldi S, Blumenthal R.
Role of viral envelope sialic acid in membrane fusion mediated by the vesicular stomatitis virus envelope glycoprotein.
Biochemistry. 31: 10108-13, 1992.
61)  Blumenthal R, Schoch C, Puri A, Clague MJ.
A dissection of steps leading to viral envelope protein-mediated membrane fusion.
Ann N Y Acad Sci. 635: 285-96, 1991.
62)  Kaplan D, Zimmerberg J, Puri A, Sarkar DP, Blumenthal R.
Single cell fusion events induced by influenza hemagglutinin: studies with rapid-flow, quantitative fluorescence microscopy.
Exp Cell Res. 195: 137-44, 1991.
63)  Herrmann A, Clague MJ, Puri A, Morris SJ, Blumenthal R, Grimaldi S.
Effect of erythrocyte transbilayer phospholipid distribution on fusion with vesicular stomatitis virus.
Biochemistry. 29: 4054-8, 1990.
64)  Blumenthal R, Bali-Puri A, Walter A, Covell D, Eidelman O.
pH-dependent fusion of vesicular stomatitis virus with Vero cells. Measurement by dequenching of octadecyl rhodamine fluorescence.
J Biol Chem. 262: 13614-9, 1987.
65)  Singhal A, Bali A, Gupta CM.
Antibody-mediated targeting of liposomes to erythrocytes in whole blood.
Biochim Biophys Acta. 880: 72-7, 1986.
66)  Agarwal K, Bali A, Gupta CM.
Effect of phospholipid structure on stability and survival times of liposomes in circulation.
Biochim Biophys Acta. 883: 468-75, 1986.
67)  Agarwal K, Bali A, Gupta CM.
Influence of the phospholipid structure on the stability of liposomes in serum.
Biochim Biophys Acta. 856: 36-40, 1986.
68)  Gupta CM, Puri A, Jain RK, Bali A, Anand N.
Protection of mice against Plasmodium berghei infection by a tuftsin derivative.
FEBS Lett. 205: 351-4, 1986.
69)  Curatolo W, Bali A, Gupta CM.
Phase behavior of carbamyloxyphosphatidylcholine, a sphingolipid analogue.
J Pharm Sci. 74: 1255-8, 1985.
70)  Singhal A, Bali A, Jain RK, Gupta CM.
Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers.
FEBS Lett. 178: 109-13, 1984.
71)  Gupta CM, Bali A.
Synthesis of carbamyl and ether analogs of phosphatidylchoines.
Chemistry and Physics of Lipids. 36: 169-77, 1984.
72)  Bali A, Dhawan S, Gupta CM.
Stability of liposomes in circulation is markedly enhanced by structural modification of their phospholipid component.
FEBS Lett. 154: 373-7, 1983.
73)  Curatolo W, Bali A, Gupta CM.
Metastable phase behavior of a sphingolipid analogue.
Biochim Biophys Acta. 690: 89-94, 1982.
74)  Gupta CM, Bali A.
Carbamyl analogs of phosphatidylcholines. Synthesis, interaction with phospholipases and permeability behavior of their liposomes.
Biochim Biophys Acta. 663: 506-15, 1981.
75)  Gupta CM, Bali A, Dhawan S.
Modification of phospholipid structure results in greater stability if liposomes in serum.
Biochim Biophys Acta. 648: 192-8, 1981.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/14/2014.